LAUSR

301 Sir, Despite recent therapeutic advances, remission induction after myeloma relapse remains a major clinical challenge. Treatment of relapsed refractory multiple myeloma (RRMM) in the background of resistance to immunomodulators and bortezomib usually results in inferior outcomes.[1] The use of newer drugs such as pomalidomide, carfilzomib, and daratumumab in the management of RRMM has yielded unprecedented results and provided hope of achieving deeper and durable responses. Daratumumab, a humanized monoclonal antibody that targets CD38 receptors present on myeloma cells, has shown exceptional efficacy in RRMM as monotherapy and combination with conventional anti‐myeloma regimens.[2] Combination of daratumumab with pomalidomide and dexamethasone has been recently approved by the US Food and Drug Administration in RRMM patients who have received at least two prior therapies.[3] Its recent availability in India has ushered a new optimism in the management of RRMM patients who otherwise had limited therapeutic options.[4]